โ† Wiki Index / Microbiology & Immunology / Type III Secretion System Injectisome
๐Ÿฆ  Microbiology & Immunology

Type III Secretion System Injectisome

The type III secretion system injectisome is a macromolecular syringe-like nanomachine employed by Gram-negative bacterial pathogens to deliver effector proteins directly into eukaryotic host cell cytoplasm.

Type III secretion system injectisome is a multi-protein macromolecular nanomachine evolved by diverse Gram-negative bacterial pathogens to translocate bacterial effector proteins across host cellular membranes directly into the eukaryotic cytosol. Found in clinically significant genera such as Salmonella, Shigella, Yersinia, Pseudomonas, and enteropathogenic Escherichia coli, the injectisome shares deep evolutionary homology with the bacterial flagellar motor basal body. By subverting host signal transduction pathways, actin cytoskeletal dynamics, and innate immune defenses, the injected effector proteins promote bacterial internalization, intracellular survival, or immune evasion.

The injectisome operates as a specialized molecular syringe spanning three biological barriers: the bacterial inner membrane, the periplasm and peptidoglycan layer, and the bacterial outer membrane, culminating in a hollow extracellular needle that interfaces directly with the eukaryotic plasma membrane. Decades of biochemical, genetic, and cryo-electron microscopy investigations have elucidated the molecular mechanisms governing needle assembly, substrate recognition, and the hierarchical secretion switch that regulates translocation upon host cell contact.

Architectural Anatomy of the Needle Complex

The injectisome comprises more than twenty distinct structural proteins organized into concentric ring assemblies and an elongated hollow filament, displaying a total molecular mass exceeding 3.5 megadaltons.

Molecular Architecture of the Bacterial Injectisome:
[Eukaryotic Cell Plasma Membrane]
||
[Translocon Pore: PopB / PopD]
||
[Extracellular Hollow Needle: PrgI] (~60-80 nm)
||
+-------------------------------------+
| Outer Membrane Secretin Ring: InvG |
+-------------------------------------+
| Periplasmic Peptidoglycan Collar |
+-------------------------------------+
| Inner Membrane MS Ring: PrgH / PrgK |
+-------------------------------------+
| Export Apparatus Core: InvA, SpaS |
+-------------------------------------+
| Cytoplasmic Sorting Platform / ATPase|
+-------------------------------------+
[Bacterial Cytoplasm & Effector Chaperones]

The basal body anchors the nanomachine in the bacterial envelope. The inner membrane ring (MS ring), composed of proteins such as PrgH and PrgK in Salmonella, coordinates with a centralized export apparatus consisting of five conserved hydrophobic membrane proteins. Surrounding the export core on the cytoplasmic face is a specialized hexameric ATPase complex (such as InvC) that provides the proton-motive force and chemical energy necessary to unfold effector proteins and guide them into the secretion conduit. Spanning the outer membrane is the secretin ring (composed of InvG multimers), forming an aqueous channel through the lipid bilayer. Extending outward from the secretin is the rigid, hollow needle filament, composed of hundreds of helical subunits of a small protein (such as PrgI or MxiH) that creates a central lumen roughly 2 to 3 nanometers in diameter.

Assembly Hierarchy and the Substrate Secretion Switch

Assembly of the injectisome proceeds in a tightly orchestrated chronological sequence, controlled by an internal substrate-switching mechanism that distinguishes structural components from early, intermediate, and late virulence effectors.

The basal body and export apparatus assemble first, establishing a functional secretion channel across the bacterial envelope. The export apparatus initially recognizes and secretes needle subunit monomers. These subunits travel through the central pore of the growing filament, polymerizing at the distal tip under the guidance of a specialized cap protein. To prevent indefinite elongation, an internal molecular ruler protein (such as InvJ in Salmonella or YscP in Yersinia) monitors needle length. Once the filament reaches approximately 60 to 80 nanometers, the ruler protein interacts with the inner membrane gate protein (such as SpaS), triggering a major conformational shift that switches secretion specificity from needle components to translocon and effector proteins.

Host Membrane Insertion via the Translocon Pore

Secretion remains paused in a primed state until the tip of the needle makes physical contact with the eukaryotic plasma membrane. Contact sensing induces the secretion of translocator proteins (such as SipB/SipC in Salmonella or YopB/YopD in Yersinia).

These amphipathic proteins insert directly into the host cholesterol-rich lipid bilayer, oligomerizing to form a continuous proteinaceous translocon pore measuring approximately 3 to 5 nanometers across. The needle tip locks onto the translocon pore, forming a sealed, contiguous conduits from the bacterial cytoplasm to the host cell interior. Effector proteins are unfolded by the cytoplasmic ATPase, threaded through the narrow needle lumen in an extended polypeptide state, and refolded inside the eukaryotic cytosol, ensuring that toxic effectors never leak into the extracellular milieu.

Pathogenic Effector Functions and Host Subversion

Once delivered into the eukaryotic cytosol, effector proteins target fundamental mammalian biochemical pathways to alter host cell biology in favor of the invading pathogen.

In enteric pathogens such as Salmonella enterica, effectors like SopE, SopE2, and SopB act as guanine nucleotide exchange factors and phosphoinositide phosphatases that activate host Rho-family GTPases (Cdc42 and Rac1). This induces localized actin cytoskeletal rearrangements, producing membrane ruffles that engulf non-phagocytic epithelial cells in a process termed bacterial-mediated endocytosis. Conversely, Yersinia species translocate effectors like YopE (a GTPase-activating protein) and YopH (a potent protein tyrosine phosphatase) to paralyze the actin cytoskeleton and dismantle focal adhesions, preventing host macrophages from executing phagocytosis.

Therapeutic Targeting and Anti-Virulence Strategies

Because the injectisome is required for virulence in many pathogenic bacteria while remaining absent from commensal microflora and eukaryotic cells, it represents an attractive target for novel anti-infective therapies.

Traditional broad-spectrum antibiotics kill bacteria or inhibit growth, exerting strong selective pressure that drives the evolution of antimicrobial resistance (AMR). In contrast, anti-virulence therapeutics targeting the type III secretion system disarm the pathogen's ability to infect host cells without directly threatening bacterial viability, substantially reducing evolutionary pressure for resistance. Small-molecule inhibitors that block the export ATPase, prevent secretin ring multimerization, or disrupt needle assembly have demonstrated significant efficacy in preclinical animal models, offering promising avenues for combating multi-drug resistant bacterial infections.

References

  1. Galรกn, J. E., & Wolf-Watz, H. (2006). Protein delivery into eukaryotic cells by type III secretion machines. Nature, 444(7119), 567โ€“573. doi:10.1038/nature05272
  2. Cornelis, G. R. (2006). The type III secretion injectisome. Nature Reviews Microbiology, 4(11), 811โ€“825. doi:10.1038/nrmicro1526
  3. Marlovits, T. C., Kubori, T., Sukhan, A., Thomas, D. R., Galรกn, J. E., & Unger, V. M. (2004). Structural insights into the assembly of the type III secretion needle complex. Science, 306(5698), 1040โ€“1042. doi:10.1126/science.1102610
๐Ÿงฌ Support Open Science
Explore interactive science games on LowKey Games or browse scientific apparel & accessories in the CRV Science Shop.
๐Ÿ’ก Spot an inaccuracy or have primary literature to expand this article?
Submit a citation or revision note using your shared CRV Science / LowKey Games profile ID.
Suggest Revision